Lumos Diagnostics Holdings (ASX:LDX) said it will start receiving Medicare reimbursement for its FebriDx rapid diagnostic test designed to distinguish bacterial from viral respiratory infections in two US regions, according to a Thursday filing with the Australian bourse.

Effective this month, the test has been included in the Medicare fee schedule in the Palmetto and Novitas regions at a rate of $41.38 per test, the filing said.

The test is reimbursable in both moderately complex and clinical laboratory improvement amendments waived settings, the company said.

Shares of the company rose about 14% in recent Thursday trade.